The Anti-dyskinetic Effect of the Clinic-ready MGluRpositive Allosteric Modulator AZD8529 in the 6-OHDA-lesioned Rat

Overview

Journal Naunyn Schmiedebergs Arch Pharmacol

Date 2025 Jan 22

PMID 39841218

Authors

Judy Shaqfah

Woojin Kang

Fleur Gaudette

Marianne Khalil

Cynthia Kwan

Sebastien Belliveau

Elodie Bourgeois-Cayer

Adjia Hamadjida

Dominique Bedard

Francis Beaudry

Philippe Huot

Affiliations

Soon will be listed here.

Abstract

L-3,4-dihydroxyphenylalanine (L-DOPA) remains the main treatment for motor symptoms of Parkinson's disease (PD). However, chronic use is associated with the development of complications such as L-DOPA-induced dyskinesia. We previously demonstrated that LY-487,379, a highly selective metabotropic glutamate receptor 2 (mGluR2) positive allosteric modulator (PAM), reduces the severity of L-DOPA-induced abnormal involuntary movements (AIMs) in the 6-hydroxydopamine (6-OHDA)-lesioned rat model of PD, without interfering with the anti-parkinsonian action of L-DOPA. Here, we seek to determine the effect of AZD8529, another highly selective mGluR2 PAM, on L-DOPA-induced AIMs in the 6-OHDA-lesioned rat. Unlike LY-487,379, AZD8529 has previously undergone clinical trials and could therefore be repurposed if proven efficacious in pre-clinical studies. We first determined the pharmacokinetic (PK) profile of AZD8529 to administer doses leading to clinically relevant plasma levels in the behavioural studies. Then, dyskinetic 6-OHDAlesioned rats were administered AZD8529 (0.1, 0.3, and 1 mg/kg) or vehicle in combination with L-DOPA followed by assessment of AIMs severity. The cylinder test was then used to evaluate the effect of AZD8529 on the anti-parkinsonian action of L-DOPA. We found that AZD8529 (0.1, 0.3 and 1 mg/kg) in combination with L-DOPA significantly reduced the severity of AIMs duration (P < 0.05), but not amplitude, when compared to L-DOPA/vehicle. AZD8529 administration did not interfere with L-DOPA anti-parkinsonian action. Our results provide evidence that mGluR2 positive allosteric modulation with AZD8529 may be a viable, yet relatively modest, treatment strategy to alleviate L-DOPA-induced.

References

Acri J, Cross A, Skolnick P . From bench to bedside: mGluR2 positive allosteric modulators as medications to treat substance use disorders. Psychopharmacology (Berl). 2016; 234(9-10):1347-1355. DOI: 10.1007/s00213-016-4501-9. View

Ahlskog J, Muenter M . Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord. 2001; 16(3):448-58. DOI: 10.1002/mds.1090. View

Anwyl R . Metabotropic glutamate receptors: electrophysiological properties and role in plasticity. Brain Res Brain Res Rev. 1999; 29(1):83-120. DOI: 10.1016/s0165-0173(98)00050-2. View

Bespalov A, Muller R, Relo A, Hudzik T . Drug Tolerance: A Known Unknown in Translational Neuroscience. Trends Pharmacol Sci. 2016; 37(5):364-378. DOI: 10.1016/j.tips.2016.01.008. View

Bezard E, Brotchie J, Gross C . Pathophysiology of levodopa-induced dyskinesia: potential for new therapies. Nat Rev Neurosci. 2001; 2(8):577-88. DOI: 10.1038/35086062. View

Cenci M . Glutamatergic pathways as a target for the treatment of dyskinesias in Parkinson's disease. Biochem Soc Trans. 2014; 42(2):600-4. DOI: 10.1042/BST20140006. View

Conn P, Pin J . Pharmacology and functions of metabotropic glutamate receptors. Annu Rev Pharmacol Toxicol. 1997; 37:205-37. DOI: 10.1146/annurev.pharmtox.37.1.205. View

COTZIAS G, VAN WOERT M, Schiffer L . Aromatic amino acids and modification of parkinsonism. N Engl J Med. 1967; 276(7):374-9. DOI: 10.1056/NEJM196702162760703. View

COTZIAS G, PAPAVASILIOU P, GELLENE R . Modification of Parkinsonism--chronic treatment with L-dopa. N Engl J Med. 1969; 280(7):337-45. DOI: 10.1056/NEJM196902132800701. View

10.

Fabbrini G, Brotchie J, Grandas F, Nomoto M, Goetz C . Levodopa-induced dyskinesias. Mov Disord. 2007; 22(10):1379-1389. DOI: 10.1002/mds.21475. View

11.

Fox S, Katzenschlager R, Lim S, Barton B, de Bie R, Seppi K . International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson's disease. Mov Disord. 2018; 33(8):1248-1266. DOI: 10.1002/mds.27372. View

12.

Frouni I, Hamadjida A, Kwan C, Bedard D, Nafade V, Gaudette F . Activation of mGlu receptors, a novel therapeutic approach to alleviate dyskinesia and psychosis in experimental parkinsonism. Neuropharmacology. 2019; 158:107725. DOI: 10.1016/j.neuropharm.2019.107725. View

13.

Frouni I, Kwan C, Bedard D, Belliveau S, Bourgeois-Cayer E, Gaudette F . Effect of the selective 5-HT receptor antagonist EMD-281,014 on L-DOPA-induced abnormal involuntary movements in the 6-OHDA-lesioned rat. Exp Brain Res. 2018; 237(1):29-36. DOI: 10.1007/s00221-018-5390-4. View

14.

Frouni I, Kwan C, Nuara S, Belliveau S, Kang W, Hamadjida A . Effect of the mGlu positive allosteric modulator CBiPES on dyskinesia, psychosis-like behaviours and parkinsonism in the MPTP-lesioned marmoset. J Neural Transm (Vienna). 2021; 128(1):73-81. DOI: 10.1007/s00702-020-02287-8. View

15.

Hamadjida A, Frouni I, Kwan C, Huot P . Classic animal models of Parkinson's disease: a historical perspective. Behav Pharmacol. 2018; 30(4):291-310. DOI: 10.1097/FBP.0000000000000441. View

16.

Hamadjida A, Sid-Otmane L, Kwan C, Frouni I, Nafade V, Bedard D . The highly selective mGlu receptor positive allosteric modulator LY-487,379 alleviates l-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson's disease. Eur J Neurosci. 2020; 51(12):2412-2422. DOI: 10.1111/ejn.14679. View

17.

Hauser R, Pahwa R, Tanner C, Oertel W, Isaacson S, Johnson R . ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson's Disease (EASE LID 2 Study): Interim Results of an Open-Label Safety Study. J Parkinsons Dis. 2017; 7(3):511-522. PMC: 5611804. DOI: 10.3233/JPD-171134. View

18.

Hely M, Morris J, Reid W, Trafficante R . Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years. Mov Disord. 2004; 20(2):190-9. DOI: 10.1002/mds.20324. View

19.

Huot P, Johnston T, Koprich J, Fox S, Brotchie J . The pharmacology of L-DOPA-induced dyskinesia in Parkinson's disease. Pharmacol Rev. 2013; 65(1):171-222. DOI: 10.1124/pr.111.005678. View

20.

Huot P, Johnston T, Koprich J, Espinosa M, Reyes M, Fox S . L-745,870 reduces the expression of abnormal involuntary movements in the 6-OHDA-lesioned rat. Behav Pharmacol. 2014; 26(1-2):101-8. DOI: 10.1097/FBP.0000000000000096. View